Center Report to the SNMMI Board of Directors
January 2020

RADIOPHARMACEUTICAL SCIENCES COUNCIL

Council Mission: The Radiopharmaceutical Sciences Council, hereafter referred to as the Council, is a group within The Society of Nuclear Medicine and Molecular Imaging, Inc., hereafter referred to as the Society, dedicated to the interchange of scientific and medical information, ideas and knowledge among Society members who have interest in radiopharmaceutical sciences. The overall mission of the Radiopharmaceutical Sciences Council is to:

(a) provide a forum for members with similar interests
(b) provide expertise in the field of interest to the membership
(c) foster education in research and application of radiopharmaceutical sciences
(d) provide outreach to other professionals, organizations and industrial partners
(e) nurture new membership into the Society and the Council
(f) provide recognition for professionals who have made outstanding contributions in the fields encompassed by the radiopharmaceutical sciences, and provide recognition and incentives for early stage investigators/scientists who have demonstrated their potentials in the radiopharmaceutical fields
(g) serve as a resource to SNMMI Leadership

Council Mission and SNMMI’s Strategic Plan: The work of the Radiopharmaceutical Sciences Council, applies to the following goals and objectives in SNMMI’s Strategic Plan:

Goal B: SNMMI has advanced the development and approval of nuclear medicine and molecular imaging technologies.

Objective 1: Encourage and promote research in the field.
   a. Increase the number of facilitated collaborative research efforts among academic sites with industry.
   b. Identify non-proprietary tracers that academic sites can help move to approval.
   c. Reach out to experts in the field to involve them in work groups or coalitions that are producing new studies and papers.
   d. Support and foster collaboration between academia and industry; academia looks to industry to translate initial discoveries in patient care into new technology.

Objective 2: Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics and instrumentation.
   a. Organize meetings/events to involve experts from the field in identifying high-impact, unmet clinical needs.
   b. Provide essential knowledge/workshops to translate highly-demanded radiopharmaceuticals into clinical use in term of production details and regulation compliance

Goal F: SNMMI has the organizational strength and sustainability to lead the field in a dynamic healthcare landscape.

Objective 1: Strengthen membership numbers.
   d. Ensure enthusiasm.
iii. Create a sense of community and networking opportunities among our members.

RPSC Council President: Peter Scott, PhD

RPSC Intern/Mentor: Jessica Comstock, PharmD/Pedro Brugarolas, PhD

Date of Last meeting: December 2019

Date of Next meeting: March 14, 2020 RPSC Retreat, Reston, VA

Update on Council Programs:

2020 Mid-Winter Meeting CE Sessions:
- Development Pipeline of a New Radiopharmaceutical Drug-From Concept to Reimbursement

2020 SNMMI Annual Meeting Categorical:
- Labeling Strategies for Radiopharmaceutical Synthesis: State-of-the-art and prospects

2020 SNMMI Annual Meeting CE Session:
- Validating a Radiotracer
- Michael J. Welch Award Presentation and Lecture
- Leadership Skills
- PSMA Updates
- QC Nuts & Bolts

Action Items in Progress/Pending:
- 2020 RPSC Awards:
  - Michael J. Welch Travel Grant: (TBD in March 2020 after abstract submission deadline)
  - Michael J. Welch Award: Henry VanBrooklin, PhD
  - Berson-Yalow Award: (TBD in March 2020 after abstract submission deadline)
  - RPSC Young Investigator Award: TBD (awarded during SNMMI AM)

Action Items Completed: See programs above

Recommendations/Questions for the Board of Directors: N/A

Other Comments: N/A